CL2012002852A1 - Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico. - Google Patents

Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico.

Info

Publication number
CL2012002852A1
CL2012002852A1 CL2012002852A CL2012002852A CL2012002852A1 CL 2012002852 A1 CL2012002852 A1 CL 2012002852A1 CL 2012002852 A CL2012002852 A CL 2012002852A CL 2012002852 A CL2012002852 A CL 2012002852A CL 2012002852 A1 CL2012002852 A1 CL 2012002852A1
Authority
CL
Chile
Prior art keywords
brain
disease
measuring
therapeutic agent
rate
Prior art date
Application number
CL2012002852A
Other languages
English (en)
Inventor
Norman R Relkin
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44761427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002852(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of CL2012002852A1 publication Critical patent/CL2012002852A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Developmental Disabilities (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

Método de tratamiento de la enfermedad de Alzheimer midiendo el índice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapéutico.
CL2012002852A 2010-04-13 2012-10-11 Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico. CL2012002852A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32373910P 2010-04-13 2010-04-13

Publications (1)

Publication Number Publication Date
CL2012002852A1 true CL2012002852A1 (es) 2013-04-05

Family

ID=44761427

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002852A CL2012002852A1 (es) 2010-04-13 2012-10-11 Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico.

Country Status (17)

Country Link
US (2) US8066993B2 (es)
EP (1) EP2451348A4 (es)
JP (2) JP2013509985A (es)
KR (1) KR20130114563A (es)
CN (1) CN102946799A (es)
AR (1) AR081534A1 (es)
AU (1) AU2011240556B2 (es)
BR (1) BR112012026224A2 (es)
CA (1) CA2795651A1 (es)
CL (1) CL2012002852A1 (es)
CO (1) CO6592030A2 (es)
EA (1) EA201291040A1 (es)
IL (1) IL222245A0 (es)
MX (1) MX2012011924A (es)
SG (1) SG184820A1 (es)
TW (1) TW201138807A (es)
WO (1) WO2011130355A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP2742855A1 (en) * 2012-12-11 2014-06-18 Friedrich-Alexander-Universität Erlangen-Nürnberg Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
CN106163548A (zh) * 2014-02-08 2016-11-23 健泰科生物技术公司 治疗阿尔茨海默氏病的方法
JP6548615B2 (ja) * 2016-08-23 2019-07-24 富士フイルム株式会社 磁場歪み算出装置、方法およびプログラム
CN108830830A (zh) * 2018-05-11 2018-11-16 深圳博脑医疗科技有限公司 一种脑萎缩程度的定量检测方法、检测装置及终端设备
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003064395A1 (ja) * 2002-01-31 2005-05-26 国立精神・神経センター総長 神経変性疾患の予防又は治療剤
BRPI0517672A (pt) * 2004-11-05 2008-10-14 Wyeth Corp modalidades de formação de imagens para seleção terapêutica de doença de alzheimer
JP5889529B2 (ja) * 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
ES2477294T3 (es) * 2007-08-13 2014-07-16 Baxter International Inc Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe

Also Published As

Publication number Publication date
US8066993B2 (en) 2011-11-29
IL222245A0 (en) 2012-12-31
US8722042B2 (en) 2014-05-13
US20110251479A1 (en) 2011-10-13
CA2795651A1 (en) 2011-10-20
KR20130114563A (ko) 2013-10-17
SG184820A1 (en) 2012-11-29
AU2011240556B2 (en) 2012-06-21
JP2012210413A (ja) 2012-11-01
JP2013509985A (ja) 2013-03-21
EP2451348A4 (en) 2013-07-31
AU2011240556A1 (en) 2012-04-19
CO6592030A2 (es) 2013-01-02
TW201138807A (en) 2011-11-16
EA201291040A1 (ru) 2013-04-30
BR112012026224A2 (pt) 2016-07-12
WO2011130355A1 (en) 2011-10-20
MX2012011924A (es) 2013-03-05
AR081534A1 (es) 2012-10-03
CN102946799A (zh) 2013-02-27
EP2451348A1 (en) 2012-05-16
US20120071747A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CL2012002852A1 (es) Metodo de tratamiento de la enfermedad de alzheimer midiendo el indice de agrandamiento ventricular en el cerebro usando inmunoglobulina intravenosa como agente terapeutico.
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
IL269511A (en) New therapeutic approaches to treat Parkinson's disease
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
EA201492052A1 (ru) Лечение миелосупрессии
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
WO2014025681A3 (en) Devices and methods for wearable injection guides
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
NZ626937A (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
NZ630367A (en) Methods of treatment of pediatric solid tumor
PT2994160T (pt) Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
EP2946792A4 (en) THERAPEUTIC AGENT AND THERAPY PROCEDURE WITH 1,25D3 MARRS FOR NEUROLOGICAL ILLNESSES SUCH AS MORBUS ALZHEIMER
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
EP2987496A4 (en) COGNITIVE DISORDER TREATMENT AGENT, BASED ON BETA-AMYLOID PROTEIN, THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE AND CORRESPONDING TREATMENT METHOD AND PATHOLOGICAL ANALYSIS METHOD
RU2015104076A (ru) Композиция с факторами роста для применения в интраназальном лечении нейродегенеративного заболевания или других заболеваний центральной нервной системы и способ ее получения
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
UA98863U (en) Method for treating endometrial hyperplasia of patients of reproductive age